Immixbiopharma Invest Information

Immix Biopharma's NXC-201 Shows Promising Results for AL Amyloidosis in Clinical Study May 11, 2024

Immix Biopharma Sets $15 Million Public Offering Price for Common Stock Feb 6, 2024

FDA Greenlights Immix Biopharma's IND for CAR-T Therapy NXC-201, Paving the Way for US Clinical Trials Nov 21, 2023